"What we will say, is that the drug takes an approach that – right now – no other company is taking, and we feel that this approach is part of the reason many are denouncing Anavex’s chances of success. Specifically, if it proves correct, it will basically render other drug candidates in the space as useless, and suggest that some of the largest companies in healthcare have wasted billions of dollars barking up the wrong tree." :-D